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cases of active TB occurred during follow-up in patients
with positive baseline screening. Among the 63(54.8%)
patients who screened negative, 2(3.2%) developed ac-
tive TB (under infliximab and adalimu mab) more than
one year after initiation of biologics. 26(41.3%) patients
were re-screened at the TB centre. 5(19.2%) had tu-
berculin skin test (TST) conversion and one concomi-
tantly undetermined IGRA. No IGRA conversions were
observed. The follow-up period was 4.0 years. TB base-
line screening’s negative predictive value (NPV) was
96.8% (95%CI: 89.0% to 99.5%). A low rate of re-
screening was observed. 
Conclusion: The rate of latent TB at baseline screening
was higher than expected. Preventive treatment was
well tolerated. No patients with positive baseline
screening developed active TB. Efforts should be made
to raise awareness concerning the risk of TB exposure,
specially considering that the active TB cases were com-
patible with new infection. The rate of re-screening sug-
gests a low awareness regarding current recomenda-
tion. Nation-wide studies are necessary to evaluate the
efficacy of the re-screening strategy and to clarify what
risk groups most benefit from it.
Keywords: Screening; Latent tuberculosis; Biological
agents; Anti-tumor necrosis factor-alpha therapy; Tu-
berculosis
IntroductIon
The advent of biological therapies has greatly improved
the treatment and management of immunomediated
diseases such as Crohn’s disease, psoriasis, rheumatoid
arthritis, ankylosing spondylitis and multiple sclero-
sis1-3, allowing for a better quality of life for these pa-
tients4. Biologic drugs are now a staple in the clinical
appro ach to severe forms of these diseases. However,
they require careful management given their suppres-
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AbstrAct 
Aim: Biological therapies are a risk factor for tubercu-
losis (TB). Portuguese recommendations endorse uni-
versal baseline screening for TB, before starting bio-
logics (2006) and annually thereafter if screened nega-
tive (2012 update). The gain with re-screening remains
unknown. We aimed to: i) identify the risk of latent TB
infection at baseline screening among patients candi-
dates to initiate biologics; ii) present follow-up results
for patients receiving different biological therapies and
analyse intolerance or toxicity related to preventive
therapy, conversions of immunodiagnostic tests under
biological therapy and development of active TB. 
Methods: Patients screened for TB at a reference cen-
tre before starting biological therapy between 2008-
-2012 were identified. Medical files were retrospec-
tively reviewed. Demographic data, screening and fol-
low-up results and information on biological therapy
were collected.
Results: 183 patients were included in the study, with
115 starting biological therapy. The baseline screening
was positive in 52(45.2%) patients – 50(96.2%) were
proposed for preventive treatment (2 had abnormal li -
ver enzymes). Mild hepatotoxicity occurred in 4(8%)
patients without need to interrupt TB prophylaxis. No
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sive effect on the patient’s immune system5. Therefore,
they pose as a risk factor for the development of active
tuberculosis (TB)6,7.
Medical societies have introduced recommenda-
tions for screening of latent tuberculosis infection befo -
re initiation of biological therapy6,8. Portugal is a coun -
try with an intermediate incidence of TB (25.2/100
000 habitants, data of 2012)9. National recommenda-
tions published in 200610 consisted of a TB screening
prior to the initiation of biological therapy as well as
an annual screening afterwards for those with a nega-
tive baseline screening, for as long, as the therapy is
maintained (updated in 2012)11,12. Patients with a po -
sitive baseline screening must be regularly questioned
by their assistant physicians in order to identify recent
TB exposure with the shortest delay possible12.
The effectiveness of the baseline screening has been
confirmed13,14, but to date the gain in the annual 
re-scre ening strategy remains unknown.
The present study was conducted at an urban refe -
rence centre for TB. This TB centre is responsible for
the management of all outpatients TB cases in the re-
gion and the screening of risk populations. An exis -
ting regional network crosses information of active TB
cases diagnosed by clinical or laboratorial means as
well as by epidemiologic inquiries ensuring notifica-
tion of all diagnosed cases. Patients who are candidates
for initiation of biological therapy are sent to the refe -
rence centre by their assistant physician in order to be
screened for TB before the beginning of the therapy.
Contact between the assistant physician and the
referen ce centre doctor is promoted in the daily clini-
cal practice.
The aim of this study was to identify the risk of la-
tent tuberculosis infection (LTBI) at baseline screen-
ing among patients candidates to initiate biological
therapies and to present the follow-up results for pa-
tients receiving different biological therapies (either
with positive or negative screening). We analysed in-
tolerance or toxicity related to preventive therapy, con-
versions of immunodiagnostic tests for those with a
negative baseline screening and development of active
TB for all.
Methods
Clinical files of all patients that have been screened for
TB at the reference TB centre as candidates to start bio -
logical therapy, between January 2008 and December
2012, were retrospectively reviewed. All patients were
followed in order to evaluate development of active
TB, intolerance or toxicity related to preventive thera-
py and seroconversions among those with a negative
screening (annual re-screening). The follow-up of the
study was concluded in 2014. 
Exclusion criteria was unavailability of information
regarding initiation of biologic therapy.  
After exclusion of active TB, screening methodolo-
gy includes a detailed medical history, physical exami -
nation, chest radiography, tuberculin skin test (TST)
and interferon-γ release assay (IGRA). A positive TST
was considered when the diameter of the transverse
induration surpassed 10mm in immunocompetent pa-
tients or 5mm in immunosuppressed patients. Quan-
tiferon-TB Gold in-tube (Cellestis Ltd, Victoria, Aus-
tralia) was used to determine the QTF assay according
to manufacturer’s instructions. IGRA was considered to
be posi tive if IFN-γ ≥0.35 IU/ml. All patients with past
non-treated TB, recent TB exposure or a positive TST
or IGRA were offered preventive therapy, after exclu-
sion of risk factors for toxicity.
Patients were considered immunosuppressed when
receiving immunosuppressive therapy, such as corti-
costeroids in doses >15mg/day for more than 2 weeks. 
The demographic and clinical data of the patients,
baseline screening, follow-up results and information
regarding the biological therapy were collected from
clinical records. 
stAtIstIcAl AnAlysIs
A descriptive analysis of outcomes and prevalence
study of tuberculosis was performed in the patients
who started biological therapy. Continuous variables
are expressed as mean± standard deviation (SD), while
nominal variables are presented in absolute and per-
centage values (%). Statistical analysis was conducted
using SPSS Statistics V.22.0 for Windows software
package.  
results
During the studied period, 183 patients were inclu -
ded (38.8% with dermatological, 29.5% with gas-
troenterological, 16.9%  with rheumatological, and
14.7% with neurological diseases). From these, 115
(62.8%) patients did start biological therapy. The mean
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± standard deviation of the age of the 115 patients who
initiated biological therapy was 41 ± 11.5 years-old
(min=18 years-old, max= 67 years-old). The mean fol-
low-up period of this study was 4.0 years.
The baseline screening of the 115 patients who star -
ted biological therapy proved to be negative in 63
(54.8%) patients and positive in 52 (45.2%) (Table I).
All 52 patients with positive screening were considered
for preventive treatment – 2 patients did not receive
treatment due to hepatic co-morbidity. The regimens
used for preventive therapy included 9 months of iso-
niazid (92%), 3 months isoniazid-rifampicin (4%), 4
months of rifampicin (2%) and 12 months isoniazid
(2%). Toxicity was reported in 5 (10%) cases. Hepato-
toxicity was found in 4 cases but all completed their
treatment successfully. One patient had dermatologic
toxicity and was unable to complete his treatment. In
all cases the situation was rapidly resolved and there
was no need for hospitalization. One patient aban-
doned preventive treatment after 2 months of isoniazid
without reported adverse events.
Out of the 63 patients with negative baseline screen-
ing, 26 (41.3%) patients were re-screened on follow-up
at the reference centre. 5 (19.2%) cases of TST con-
version occurred during follow-up and 1 (3.9%) case
had concomitant undetermined IGRA. Regarding the
cases of TST conversion, 3 patients were female, mean
age of 29.2 (min=22, max=32). None had previous TB
history nor past exposure. 2 patients had multiple scle-
rosis, other 2 had psoriasis and 1 had Crohn’s disease.
They were treated with natalizumab (2), infliximab (2)
and etanercept (1). New TB exposure since the baseline
screening was not reported.  No IGRA conversions were
observed. The follow-up screening results are summa-
rized in Table II.
No cases of active TB were observed in the patients
with positive baseline screening until conclusion of fol-
low-up. There were 2 (3.2%) reported cases of active
TB among the 63 patients with negative baseline
screening. One was male and the other female. The
younger was 37 years old and the older 61 years old.
One had Crohn’s disease and was treated with infli -
ximab, whilst the other had rheumatoid arthritis and
received adalimumab. Neither one had previous TB
history nor past exposure, but one patient reported new
TB exposure during treatment with the biologic agent.
In both cases we observed extra-pulmonary TB, name-
ly pleural and soft tissues TB. One case of active TB de-
veloped after 1 year, while the other 2 years after the be-
ginning of the treatment. Neither of these two patients
tAble I. chArActerIstIcs of the pAtIents 
who stArted bIologIcAl therApy 
N
Gender 
Total 115
Male 60 (52.2)
Female 55 (47.8)
Underlying disease
Total 115
Psoriasis 45 (39.1)
Crohn’s disease 21 (18.3)
Multiple sclerosis 21 (18.3)
Ankylosing spondylitis 12 (10.4)
Rheumatoid arthritis 8 (7)
Other 8 (7)
Immunosuppression
Total 115
Yes 62 (53.9)
No 52 (45.2)
Missing 1 (0.9)
TB exposure
Total 115
Yes 20 (17.4)
No 95 (82.6)
TB history
Total 115
None 107 (93.0)
Previous TB treatment 7 (6.1)
Sequela on the x-ray 1 (0.9)
Biological therapy
Total 115
Anti-TNFa 75 (65.2)
Etanercept 25 (33.3)
Adalimumab 24 (32.0)
Infliximab 20 (26.7)
Golimumab 6 (8.0)
Anti-CD20 3 (2.6)
Ocrelizumab 2 (66.7)
Rituximab 1 (33.3)
Other classes 37 (32.2)
Natalizumab 24 (64.9)
Ustekinumab 10 (27.0)
Tocilizumab 2 (5.4)
Efalizumab 1 (2.7)
Other diseases – hidradenitis suppurativa, necrobiosis lipoidica,
spondiloarthropathy, psoriatic arthritis, non-specified
inflammatory bowel disease
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had repeated screening after initiation of biologic the -
rapy. 
The negative predictive value (NPV) of the TB base-
line screening was 96.8% (95%CI:89.0% to 99.5%).
dIscussIon
In the group of patients who started biologic agents,
45% were found to have latent TB at the baseline
screening. The preventive treatment was mostly well
tolerated with few adverse effects. Most of the patients
undergoing biologics did not repeat screening. A high
rate of TST conversion was observed. Two cases of ac-
tive TB were diagnosed in patients with negative base-
line screening. 
The suppressive effect of biological drugs is a sig-
nificant concern, as drugs such as anti-TNF have been
shown to interfere with granuloma formation. The
granuloma is a central part of the defence mechanism
against Mycobacterium tuberculosis and the maintenance
of its structure is highly dependent of TNF. Therefore,
anti-TNF drugs decrease the host ability to defend
against the pathologic agent and the risk of developing
active TB rises5. 
The rate of latent TB at the baseline screening was
higher than expected (45.2%), when compared with
background population (15.15%)15. It is well known
that a few underlying diseases may influence TB rates.
Studies on patients with immunomediated diseases re-
ported a prevalence of LTBI ranging from 6% to
30%3,4,16. Such a result highlights the importance and
supports the need for compliance with the recom-
mendations regarding baseline screening. The baseline
screening comprises both TST and IGRA as none has
been yet proven to be clearly better for patients with
immune-mediated inflammatory diseases17.
Isoniazid is the primary preventive scheme for LTBI
treatment. Given the severity of its potential adverse
effects such as life threatening hepatotoxicity18, it is of-
ten viewed with concern by physicians. As reported in
other studies19,20, we observed that preventive treat-
ment was mostly well tolerated with few adverse effects
with only 4 patients presenting mild hepatotoxicity,
which did not prevent them from completing the treat-
ment. On the other hand, one patient developed der-
matologic toxicity. He was proposed for alternative pre-
ventive schemes with rifampicin but the attempts to
avoid toxicity were fruitless and the treatment was sus-
pended. There is the possibility that concomitant treat-
ment with isoniazid and biologics may increase the risk
of hepatotoxicity21, 22 but our patients who started bio-
logic drugs while still receiving preventive treatment
did not report pharmacologic interactions, which sup-
ports the belief that physicians may safely introduce
biologic therapy during preventive treatment. 
We observed a very good compliance with preven-
tive treatment with only two patients not completing it.
One was due to dermatologic toxicity; the other aban-
doned the treatment without reported adverse events,
after two months of isoniazid.  
Despite appropriate baseline screening, some pa-
tients may develop TB during biological therapy23,24.
Recommendations issued in 2012 advocate annual TB
tAble II. follow-up screenIng results
Baseline screening N (%)
Total 115
Positive 52 (45.2)
Negative 63 (54.8)
Repeated screening at the reference centre 26 (41.3)
TST Converted 5 (19.2)
Non converted 21 (80.8)
IGRA Converted 0
Non converted 25 (96.2)
Undetermined 1 (3.8)
Active TB 0
Did not repeat screening at the reference centre 37 (58.7)
Active TB 2 (5.4)
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screening to patients undergoing biological therapy
who had a negative baseline screening12. In our study,
only 41.3% of our patients with negative baseline
screening repeated the screening during follow-up at
the reference centre. However, we cannot fully evalua -
te compliance with the recommendations considering
that the update regarding annual screening was pu -
blished in 2012 and our study includes patients with
different treatment durations and/or who suspended
therapy before the publication of the update.
During follow-up, we observed 5 (19.2%) TST con-
versions, though only a single concomitant undeter-
mined IGRA. Similarly to findings of several studies,
the correspondence between results of TST and IGRA
is rather poor25-28. IGRA is considered the best screen-
ing tool for latent TB infection in patients receiving bio -
logic drugs, as TST carries a heavier set of con founding
factors, such as the booster effect and a lower speci-
ficity6,24,29. In addition, the patient’s underlying disease
may independently interfere with TST results. For ins -
tance, rheumatoid arthritis patients naive to biological
therapy present a reduced recall response which may
lead to false negative TST results5,26 and psoriasis pa-
tients also display a lower reactivity to TST4. However,
it is still debatable whether the IGRA results are more
accurate than TST for the TB screening of patients un-
dergoing anti-TNFa, as findings vary considerably be-
tween studies16,25,26. As IGRA relies on the production
of IFN-γ, which is known to be decreased by im-
munossupressive therapies, the effectiveness of IGRA
in detecting LTBI may consequently be reduced25,30. We
cannot, therefore, confidently consider these conver-
sions as latent TB infection, but cannot exclude the pos-
sibility either. Nevertheless, while consensus on the
best screening method is not achieved, patients with
TST conversion at re-screening represent a risk that
should not be dismissed. 
While there were no cases of active TB in patients
with positive baseline screening, 2 cases were report-
ed in patients with negative baseline screening. One
patient had rheumatoid arthritis while the other was
diagnosed with Crohn’s Disease. Both developed the
disease more than one year after the beginning of bio-
logical therapy, which suggests new infection, rather
than re-activation. Actually, one of the patients had ex-
posure to active TB while receiving the biologic agent
though it was only discovered at the time of diagnosis.
The other patient did not report exposure to TB. The
patients were being treated with infliximab and adali-
mumab. It is well known that TB development occurs
more frequently with infliximab31,32. Moreover, infli -
ximab and adalimumab are associated with the earliest
onset of the disease4. Our findings are consistent with
the literature, indicating that antibodies infliximab and
adalimumab possess a greater risk of TB progression,
when compared with soluble TNF receptor such as
etanercept2,4,32,33. This might suggest that patients un-
der these specific biological drugs require a higher de-
gree of vigilance during follow-up.
We obtained a NPV of 96.8% for the baseline TB
screening as defined in the national recommendations.
Publications in the literature have achieved similar re-
sults34. It is compatible with our findings, as our cases
of active TB were diagnosed more than one year after
initiation of biological therapy. We may therefore infer
that current baseline screening recommendations are
appropriate for identifying LTBI.  
It has been suggested that prescribers of biologics
are not sufficiently aware of the annual screening re -
commendations35. Therefore, bringing the recommen-
dations to attention of prescribers, as well as the
develop ment of a joined effort between reference cen-
tres and prescribers may increase the implementation
of the annual TB screenings.
The present study carries certain limitations, the first
being its small size. The number of patients included
in the study is not fully representative of the actual
number of patients who have received biological thera -
py during the studied period of time, as a result of a
very high proportion of unknown data regarding the
start of the biological drugs. The study also lacked a
control group of patients for result comparison. In
addi tion, very few patients repeated screening at the
reference centre, which accounts for a small number
of conversions resulting in low statistical power. We
were therefore unable to find common variables among
these patients, which might have helped in further
identifying high-risk individuals who would most
bene fit from annual re-screening. Also, our study was
performed in a country with intermediate TB inci-
dence, so our results may not apply to countries with
low TB incidence. Last but not the least, the greatest
limitation of this and most studies on latent TB screen-
ing lies in the absence of a gold standard for the diag-
nosis of latent TB.
Despite these limitations, the study has several
strong assets. First of all, it was conducted at a TB re -
ference centre that crosses information both from in-
patients and outpatients. It also includes information
from several clinical specialties that deal with biolo -
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gics, allowing for a more global understanding of the
present situation. Additionally, all cases of diagnosed
acti ve TB are notified so we can ensure that no other pa-
tients have developed the disease in the studied popu-
lation.
conclusIon
The baseline TB screening has showed a higher than ex-
pected rate of latent tuberculosis in the candidates to
start biological therapy. Adverse events were not fre-
quent and most did not interfere with the completion
of the preventive treatment. A high incidence of TST
conversions and cases of active TB has been observed,
alerting to the necessity of careful follow-up of the pa-
tients undergoing biological therapy. Moreover, both
cases of active TB suggest new infection, highlighting
the importance of the physician’s role in preventing
such outcomes. The compliance with the recommen-
dations regarding annual screening could not be fully
evaluated though it appears to not yet be implement-
ed in daily practice. Accordingly, we believe efforts
should be made to raise awareness of prescribing physi-
cians concerning the risk of exposure to TB. Mean-
while, larger nation-wide studies should be designed in
order to evaluate the efficacy of the re-screening stra -
tegy and to clarify which risk groups most benefit with
annual re-screening. 
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